BlackRock, Inc. Amendment to Schedule 13G/A for Protagonist Therapeutics, Inc.

BlackRock, Inc. filed an amendment to its Schedule 13G/A for Protagonist Therapeutics, Inc. on October 17, 2025. The filing indicates that BlackRock, Inc. beneficially owns 8,575,669 shares of common stock, representing 13.8% of the total outstanding shares. The shares are held through various business units of BlackRock, Inc. and its subsidiaries. The filing also notes that the interest of iShares Core S&P Small-Cap ETF in the common stock of Protagonist Therapeutics, Inc. is more than five percent of the total outstanding common stock. The amendment includes certifications that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.